Trial reportWorld journal of gastroenterology2005
Tumor vaccine against recurrence of hepatocellular carcinoma.
Trial report in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04521153 (Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial), which is not on this map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.Journal of cancer research and clinical oncology · 2023Pooled it
- Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials.Scientific reports · 2023Pooled it
- Specific immunotherapy in hepatocellular cancer: A systematic review.Journal of gastroenterology and hepatology · 2017Pooled it
- Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial.Annals of surgical oncology · 2020Trial
- Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.Cancer science · 2020Trial
- Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines.Cancer pathogenesis and therapy · 2025Review
- Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.BMC surgery · 2022Article
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.Journal for immunotherapy of cancer · 2021Article
- Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.Hepatobiliary surgery and nutrition · 2020Article
- Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.World journal of gastroenterology · 2019Review
- Potentiality of immunotherapy against hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.British journal of cancer · 2015Article
- Advances in non-surgical management of primary liver cancer.World journal of gastroenterology · 2014Review
- Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.Current cancer drug targets · 2012Review
- Immunotherapy of cancer in 2012.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effects of autologous tumor vaccine on recurrence of hepatocellular carcinoma (HCC).
methodsSixty patients with HCC who had undergone curative resection, were randomly divided into HCC vaccine group and control group. Three vaccinations at 2-wk intervals were performed after curative hepatic resection. Delayed-type- hypersensitivity (DTH) test was performed before and after vaccination. Primary endpoints were the time of recurrence.
resultsFour patients in control group and 6 patients in HCC vaccine group were withdrawn from the study. The vaccine containing human autologous HCC fragments showed no essential adverse effect in a phase II clinical trial and 17 of 24 patients developed a DTH response against the fragments. Three of 17 DTH-positive response patients and 5 of 7 DTH-negative response patients had recurrences after curative resection. After the operation, 1-, 2- and 3-year recurrence rates of HCC vaccine group were 16.7%, 29.2% and 33.3%, respectively. But, 1-, 2- and 3-year recurrence rates of the control group were 30.8%, 53.8% and 61.5%, respectively. The time before the first recurrence in the vaccinated patients was significantly longer than that in the control patients (P < 0.05).
conclusionAutologous tumor vaccine is of promise in decreasing recurrence of human HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.